Quantcast

Latest Biomedical Advanced Research and Development Authority Stories

2014-04-01 16:25:27

ANNAPOLIS, Md., April 1, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax(® )next-generation anthrax vaccine program were recently presented at the 8(th) Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's...

2014-03-26 08:28:41

PRINCETON, N.J., March 26, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today its financial results for the year ended December 31, 2013. Soligenix's revenues for the year ended were $3.2 million as compared to $3.1 million for...

2014-03-18 08:33:33

New Contract Reflects Successful Strategy to Diversify Customer Base ROCKVILLE, Md., March 18, 2014 /PRNewswire/ -- The EMMES Corporation today announced that it has been awarded an indefinite delivery, indefinite quantity (IDIQ) contract to become part of a clinical studies network established by the Biomedical Advanced Research and Development Authority (BARDA) to perform studies needed to develop medical countermeasures against agents of bioterrorism, pandemic influenza, and other...

2014-03-12 16:25:45

HINCKLEY, Ohio, March 12, 2014 /PRNewswire/ -- Clinical Research Management, Inc. (ClinicalRM) - a full-service Contract Research Organization (CRO) providing support for basic and applied research, clinical trials, and regulatory support - announced today it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). With this contract award ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of...

2014-03-11 08:29:04

Presentation on March 25, 2014 at 2:10 PM EDT PRINCETON, N.J., March 11, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the "Development of Thermostable Subunit Vaccines" at the...

2014-02-05 08:28:42

Presentation to be Webcast Live on February 10, 2014 at 3 PM EST PRINCETON, N.J., Feb. 5, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD,...

2014-01-16 08:26:49

Receipt of Proceeds increases January Cash Position to Approximately $6.6 million PRINCETON, N.J., Jan. 16, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well a developing several biodefense vaccines and therapeutics, announced today that it has recently received approximately $750,000, net of...

2014-01-15 08:27:45

Milestone Achieved under $9.4 Million NIAID Cooperative Grant PRINCETON, N.J., Jan. 15, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today significant steps forward in the development of ThermoVax(TM), its proprietary...

2014-01-09 08:27:11

Presentation to be Webcast Live on January 14, 2014 at 11AM PST PRINCETON, N.J., Jan. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD,...

2014-01-06 08:25:32

PRINCETON, N.J., Jan. 6, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has appointed Richard Straube, MD, as its Senior Vice President and Chief Medical Officer. Dr. Straube is a board-certified...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'